Biktarvy

Active Ingredient(s): Bictegravir + Emtricitabine + Tenofovir Alafenamide
FDA Approved: * February 7, 2018
Pharm Company: * GILEAD SCIENCES INC
Category: HIV / AIDS

Bictegravir (INN; BIC, formerly known as GS-9883)[1][2] is a second-generation integrase inhibitor (INSTI) class that was structurally derived from an earlier compound dolutegravir by scientists at Gilead Sciences; in vitro and clinical results were presented by Gilead in the summer of 2016.[3][4] In 2016, bictegravir was in a Phase 3 trial as part of a single tablet regimen in combination with tenofovir alafenamide (TAF) and emt... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Biktarvy Oral Tablet
NDC: 61958-2501
Labeler:
Gilead Sciences, Inc.
Biktarvy Oral Tablet
NDC: 61958-2505
Labeler:
Gilead Sciences, Inc.
Biktarvy Oral Tablet
NDC: 70518-3080
Labeler:
Remedyrepack Inc.